Teleflex Incorporated (NYSE:TFX) Receives $142.86 Consensus PT from Brokerages

Teleflex Incorporated (NYSE:TFX) has earned a consensus recommendation of “Hold” from the nine research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $144.00.

TFX has been the topic of several recent research reports. Truist Financial restated a “hold” rating and set a $143.00 price target (up from $135.00) on shares of Teleflex in a report on Monday. Wells Fargo & Company increased their price target on Teleflex from $130.00 to $138.00 and gave the company an “equal weight” rating in a report on Friday. Needham & Company LLC increased their price target on Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Wall Street Zen lowered Teleflex from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Mizuho set a $140.00 price target on Teleflex in a report on Friday.

Institutional Trading of Teleflex

A number of hedge funds and other institutional investors have recently bought and sold shares of TFX. AQR Capital Management LLC increased its stake in Teleflex by 478.1% in the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock worth $287,603,000 after purchasing an additional 1,956,811 shares during the period. Abrams Bison Investments LLC purchased a new stake in Teleflex in the third quarter worth $112,317,000. Norges Bank purchased a new stake in Teleflex in the fourth quarter worth $66,076,000. Thrivent Financial for Lutherans increased its stake in Teleflex by 1,161.0% in the third quarter. Thrivent Financial for Lutherans now owns 550,449 shares of the medical technology company’s stock worth $67,353,000 after purchasing an additional 506,796 shares during the period. Finally, Wolf Hill Capital Management LP purchased a new stake in Teleflex in the fourth quarter worth $47,405,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Stock Down 2.4%

NYSE TFX opened at $129.92 on Friday. The stock has a 50 day moving average price of $120.08 and a 200-day moving average price of $116.73. Teleflex has a one year low of $100.18 and a one year high of $139.67. The company has a market capitalization of $5.75 billion, a P/E ratio of -5.70, a P/E/G ratio of 0.96 and a beta of 0.82. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.03 and a current ratio of 2.55.

Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.21 by $0.18. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The company had revenue of $548.30 million for the quarter, compared to analyst estimates of $536.91 million. During the same quarter in the prior year, the firm posted $1.44 EPS. Teleflex’s quarterly revenue was up 32.3% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, equities analysts predict that Teleflex will post 6.75 EPS for the current fiscal year.

Teleflex Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Friday, March 6th were issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.0%. The ex-dividend date was Friday, March 6th. Teleflex’s dividend payout ratio is presently -5.96%.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.